ProMIS Neurosciences Inc. (PMN) Financial Statements (2026 and earlier)

Company Profile

Business Address SUITE 200, 1920 YONGE STREET
TORONTO, ON M4S 3E2
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,150,30915,432,2164,543,1708,397,35213,324,21821,569,256
Cash and cash equivalent6,116,55615,399,1654,510,1198,364,30113,291,16721,536,898
Short-term investments33,75333,05133,05133,05133,05132,358
Prepaid expense276,15042,281102,180235,011383,257473,539
Deferred costs 32,000     
Other undisclosed current assets2,723,9625,983,6504,864,1465,014,3085,203,9812,467,740
Total current assets:9,182,42121,458,1479,509,49613,646,67118,911,45624,510,535
Noncurrent Assets
Prepaid expense      
Total noncurrent assets:      
TOTAL ASSETS:9,182,42121,458,1479,509,49613,646,67118,911,45624,510,535
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,411,83112,211,0479,824,0874,056,2482,218,4252,635,087
Accounts payable2,543,4154,211,4852,780,1791,200,1621,737,4631,575,235
Accrued liabilities7,868,4167,999,5627,043,9082,856,086480,9621,059,852
Total current liabilities:10,411,83112,211,0479,824,0874,056,2482,218,4252,635,087
Noncurrent Liabilities
Liabilities, other than long-term debt29,18254,15362,395113,100199,263340,090
Deferred compensation liability, classified29,18254,15362,395113,100199,263340,090
Other undisclosed noncurrent liabilities  5,5925,5925,5925,59214,262,138
Total noncurrent liabilities:29,18259,74567,987118,692204,85514,602,228
Total liabilities:10,441,01312,270,7929,892,0744,174,9402,423,28017,237,315
Equity
Equity, attributable to parent(1,258,592)9,187,355(382,578)9,471,73116,488,1767,273,220
Additional paid in capital129,518,812129,290,671108,140,611107,877,891107,546,43398,093,270
Accumulated other comprehensive loss(371,184)(371,184)(371,184)(371,184)(371,184)(371,184)
Accumulated deficit(130,406,220)(119,732,132)(108,152,005)(98,034,976)(90,687,073)(90,448,866)
Total equity:(1,258,592)9,187,355(382,578)9,471,73116,488,1767,273,220
TOTAL LIABILITIES AND EQUITY:9,182,42121,458,1479,509,49613,646,67118,911,45624,510,535

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(10,772,119)(11,750,432)(10,184,661)(7,460,095)(6,002,445)(4,434,677)
Operating loss:(10,772,119)(11,750,432)(10,184,661)(7,460,095)(6,002,445)(4,434,677)
Nonoperating income98,031170,30667,632112,1925,764,23813,710,502
Other nonoperating income 170,30667,632112,192226,840235,912
Net income (loss) available to common stockholders, diluted:(10,674,088)(11,580,126)(10,117,029)(7,347,903)(238,207)9,275,825

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(10,674,088)(11,580,126)(10,117,029)(7,347,903)(238,207)9,275,825
Comprehensive income (loss), net of tax, attributable to parent:(10,674,088)(11,580,126)(10,117,029)(7,347,903)(238,207)9,275,825

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios